Daily pill looming for GLP-1 receptor agonists? Eli Lilly drafting TGA application
Some patients with diabetes did not want injectable therapies, said Dr Gary Deed.
Eli Lilly is preparing a TGA application for an oral GLP-1 receptor agonist to treat early diabetes following publication of phase III trial results.
The once-daily pill orforglipron reduced both average HbA1c levels and body weight after 40 weeks, according to the study published in the New England Journal of Medicine.
